- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02794064
A Prototype Tri-modal Imaging Device for Breast Cancer
Clinical Evaluation of a Prototype Tri-modal Imaging Instrument for Guiding Breast Cancer Surgery
Breast conservation surgery (BCS) is performed on patients with breast cancer with the intent to resect and completely remove the tumour while conserving as much of the surrounding normal tissue as possible. Currently, there is no way for surgeons to determine the adequacy of surgical resection in real-time during surgery; the assessment of surgical margins requires histological examination that is not available in real-time and is impractical in most clinical cases. This results in a re-excision rate of 23% among Canadian women in order to achieve optimal surgical margins. In addition, the presence or absence of cancer in tumor draining lymph nodes is recognized as a key element for breast cancer staging; however, lymph node dissection can be associated with overtreatment and morbidity (nerve damage and post surgical lymphedema) and histological analysis of nodes can be time consuming and thus delay subsequent procedures. In an effort to address these issues, we have designed and constructed, in collaboration with Sogang University, Seoul, S. Korea, a novel imaging system that performs three complementary imaging modalities (tri-modal): ultrasound (US), photoacoustic (PA) and fluorescence (FL).
This first-in-human pilot study will recruit 10 breast cancer patients undergoing breast conserving surgery at Princess Margaret Hospital (Toronto, Canada). The study is designed to test our tri-modal (US, PA, FL) imaging technology in breast cancer patients. The overall goal is to obtain initial information on the technical feasibility of the tri-modal system in a peri-operative setting and to confirm the anticipated safety of the procedures. Additionally, it will provide initial data on the ability of this system to detect/localize primary breast cancer lesions and cancer-involved lymph nodes prior to surgery.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M5T 2M9
- Princess Margaret Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Female patients with biopsy-confirmed first primary invasive unilateral breast cancer
- 18 years of age or older
- Have consented to standard of care surgery (lumpectomy, mastectomy) for primary invasive breast cancer, with or without auxiliary lymph node dissection
- Have had pre-surgical imaging of the affected breast and (where applicable) lymph notes (Note: additional imaging may also be done day of scheduled surgery i.e. mammography, nuclear medicine)
- Have existing biopsies banked at the hospital
- Surgery scheduled at Princess Margaret Hospital
- Tumor size of 1 cm or larger
Exclusion Criteria:
- Inability to provide informed consent
- Pre-operative therapy for current breast cancer (including chemotherapy, endocrine therapy and radiotherapy)
- history of other previous cancer requiring therapy (including chemotherapy, endocrine therapy and radiotherapy) within the past 12 months
- History of photosensitivity, skin disease or recurrent disease
- Pregnancy
- Absence of in-house biopsy in tissue bank
- Bilateral breast cancer
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Tri-modal imaging
Ultrasound and photoacoustic imaging of breast and adjacent lymph nodes.
Imaging time: Approximately 30 minutes
|
This tri-modal imaging system was developed in collaboration with Sogang University and is composed of three subsystems: ultrasound, photoacoustic and fluorescence.
For this study, the fluorescence subsystem will not be used.
The photoacoustic and ultrasound subsystems and data acquisition are controlled by a single workstation.
The complete system is Canadian Standards Association (CSA) certified
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Detect/localize breast tumours and lymph nodes in vivo by using tri-modal imaging
Time Frame: Baseline (tri-modal imaging), post-surgical (pathology report); an average of 1-2 weeks
|
Baseline (tri-modal imaging), post-surgical (pathology report); an average of 1-2 weeks
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 14-8692
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer Invasive Nos
-
ETOP IBCSG Partners FoundationCompleted
-
Spanish Breast Cancer Research GroupHoffmann-La Roche; Roche Farma, S.ATerminatedBreast Cancer Invasive NosSpain
-
Pomeranian Medical University SzczecinMaria Sklodowska-Curie National Research Institute of Oncology; Regional Oncology...UnknownBRCA1 Mutation | Breast Cancer Invasive NosPoland
-
McMaster UniversityCanadian Breast Cancer FoundationCompletedBreast Cancer Invasive Nos | Stage 0 Breast CarcinomaCanada
-
UNICANCERRecruitingBreast Cancer Nos Metastatic RecurrentFrance
-
University of California, San FranciscoEisai Inc.CompletedMalignant Solid Tumour | Breast Cancer Nos Metastatic Recurrent | NeuropathyUnited States
-
German Breast GroupRoche Pharma AG; Amgen; Teva Pharmaceuticals USA; Vifor PharmaCompletedInflammatory Breast Cancer | HER2 Positive Breast Cancer | Tubular Breast Cancer Stage II | Mucinous Breast Cancer Stage II | Breast Cancer Female NOS | Invasive Ductal Breast Cancer | Tubular Breast Cancer Stage IIIGermany
-
German Breast GroupCelgene Corporation; AmgenCompletedInflammatory Breast Cancer | HER2 Positive Breast Cancer | Tubular Breast Cancer Stage II | Mucinous Breast Cancer Stage II | Breast Cancer Female NOS | Invasive Ductal Breast Cancer | Tubular Breast Cancer Stage IIIGermany
-
Eastern Cooperative Oncology GroupRecruitingMelanoma | Breast Cancer, NOS | CNS Primary Tumor, NOS | Cervical Cancer, NOS | Colorectal Cancer, NOS | Leukemia, NOS | Lymphoma, NOS | Miscellaneous Neoplasm, NOS | Non-Rhabdomyosarcoma Soft Tissue Sarcoma, NOS | Testicular Nonseminomatous Germ Cell Tumor, NOS | Thyroid Cancer, NOS | Bone Cancer, NOSUnited States
-
Dana-Farber Cancer InstitutePfizerCompletedBreast Cancer Stage IV | Unresectable Locally Advanced Invasive Breast Cancer | Metastatic Invasive Breast CancerUnited States
Clinical Trials on Tri-modal imaging
-
University Health Network, TorontoCompletedThyroid Neoplasms | Thyroid Cancer | Thyroid NoduleCanada
-
King's College LondonCHDI Foundation, Inc.Recruiting
-
Unity Health TorontoUnknown
-
Peking Union Medical College HospitalUnknownRheumatoid Arthritis | UltrasonographyChina
-
Washington University School of MedicineNational Center for Complementary and Integrative Health (NCCIH)Recruiting
-
Chinese PLA General HospitalCompletedDyspepsia | Gastroesophageal Reflux Disease | Bile RefluxChina
-
University of KansasEunice Kennedy Shriver National Institute of Child Health and Human Development...Unknown
-
The Cleveland ClinicMichael J. Fox Foundation for Parkinson's ResearchCompletedParkinson DiseaseUnited States
-
Chinese University of Hong KongNot yet recruitingProstate CancerHong Kong
-
Federal University of São PauloInstituto Paulista de Estudos e Pesquisa em Oftalmologia; Eye Clinic Day Hospital...Completed